Welcome to our dedicated page for Skye Bioscience news (Ticker: SKYE), a resource for investors and traders seeking the latest updates and insights on Skye Bioscience stock.
Skye Bioscience, Inc. reports clinical-stage biotechnology developments focused on metabolic health disorders, obesity and overweight. The company's lead program, nimacimab, is a peripherally restricted monoclonal antibody inhibitor of the CB1 receptor being evaluated in the CBeyond Phase 2a program, including monotherapy and combination work with GLP-1 or other incretin-based therapies.
Recurring updates cover clinical data from CBeyond, higher-dose safety and pharmacokinetic work, regulatory feedback on follow-on trial design, manufacturing and formulation activities, scientific conference presentations, financial results and corporate outlooks. Skye also discusses its broader strategy of developing molecules that modulate G-protein-coupled receptors.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.